Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study

Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase inhibitors, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong-Wook, Saussele, Susanne, Williams, Loretta A., Mohamed, Hesham, Rong, Yuanxin, Zyczynski, Teresa, Pinilla-Ibarz, Javier, Abruzzese, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018625/
https://www.ncbi.nlm.nih.gov/pubmed/29556695
http://dx.doi.org/10.1007/s00277-018-3295-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018625/
https://www.ncbi.nlm.nih.gov/pubmed/29556695
http://dx.doi.org/10.1007/s00277-018-3295-8

Ejemplares similares